4.1 Article Proceedings Paper

Biological activity of dihydroartemisinin in canine osteosarcoma cell lines

期刊

AMERICAN JOURNAL OF VETERINARY RESEARCH
卷 69, 期 4, 页码 519-526

出版社

AMER VETERINARY MEDICAL ASSOC
DOI: 10.2460/ajvr.69.4.519

关键词

-

向作者/读者索取更多资源

Objective-To evaluate the biological activity of dihydroartemisinin on canine osteosarcoma cell lines in vitro. Sample Population-4 canine osteosarcoma cell lines. Procedures-Cell viability assays were performed on canine osteosarcoma cell lines CSCA2, OSCA16, OSCA50, and D17 after 24, 48, and 72 hours of treatment with dihydroartemisinin at concentrations of 0.1 to 100 mu M. Apoptosis was assessed by use of an ELISA for free nuclosomal DNA fragmentation and by western blot analysis for cleavage of caspase 3. Cell cycle analysis was performed by use of staining with propidium iodide and flow cytometry. Detection of reactive oxygen species (ROS) was conducted in the D17 cell line by use of 6-carboxy-2',7'-dihydrofluorescein diacetate and flow cytometry. Results-The concentration of dihydroartemisinin required for 50% inhibition of cell viability (IC50) was achieved in all 4 canine osteosarcoma cell lines and ranged from 8.7 to 43.6 mu M. Induction of apoptosis was evident as an increase in nucleosomal DNA fragmentation, cleavage of caspase 3, and an increase in the population in the sub G(0)/G(1) phase of the cell cycle detected by flow cytometry. Exposure to dihydroartemisinin also resulted in a decrease in the G(0)/G(1) population. Iron-dependent generation of ROS was detected in dihydroartemisinin-treated D17 cells; ROS generation increased in a dose-dependent manner. Conclusions and Clinical Relevance-Incubation with dihydroartemisinin resulted in biological activity against canine osteosarcoma cell lines, which included induction of apoptosis and arrest of the cell cycle. Clinical trials of dihydroartemisinin in dogs with osteosarcoma should be conducted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据